Anne E. Borgman, M.D.
Anne E. Borgman, M.D., has served on the Board since October 2022 and currently serves on the Board of Directors of NextCure, Inc. She is the principal owner of AEB Hematology Oncology Development Consulting. Dr. Borgman has extensive experience in all phases of oncology drug development of small molecules, antibodies and combinations at large and small companies across the biotech and pharmaceutical industries which includes nine regulatory approvals. Previously, Dr. Borgman served as Vice President and Therapeutic Area Head of Oncology, Hematology, and Transplant Research and Development at Jazz Pharmaceuticals. As Vice President of Research & Development at Exelixis Biopharmaceuticals, Inc., Dr. Borgman was the clinical lead responsible for global drug development in oncology for cabozantinib, a multi-targeted tyrosine kinase inhibitor. She was Associate Chief Medical Officer at KaloBios Pharmaceuticals, and Vice President and Chief Medical Officer at Talon Therapeutics (formerly Hana Biosciences). Dr. Borgman held various medical director roles at Abbott Laboratories including Global Project Head of Oncology, where she created the early development strategies for venetoclax and veliparib.
Dr. Borgman received a B.S. in biochemistry from University of Illinois, Urbana-Champaign and her M.D. from Loyola University Chicago Stritch School of Medicine. She completed her residency in pediatrics at the Baylor College of Medicine in Houston, Texas, and her fellowship in pediatric hematology-oncology and bone marrow transplantation at the David Geffen School of Medicine at UCLA. Dr. Borgman is a graduate of the Stanford Executive Program and an alumni of Stanford University’s Graduate School of Business.
Nominating and Governance